Osimertinib Plus Savolitinib for EGFR-Mutated, MET-Amplified NSCLC After Disease Progression on EGFR Tyrosine Kinase Inhibitors
A recent study has found activity and an acceptable risk-benefit profile with the combination of osimertinib and savolitinib in patients with NSCLC who had disease progression after treatment...
HSD3B1 Genotype and Its Effect on Castration Resistance and Overall Survival in Prostate Cancer
The CHAARTED trial has found that the HSD3B1 genotype is associated with earlier onset of castration resistance and poorer overall survival in men with metastatic prostate cancer...
H pylori Infection and Gastric Cancer Risk
This week on The ASCO Post Podcast, we’ll discuss a Korean trial that looked at the role of H pylori infection and gastric cancer risk...
No Improved Pathologic Complete Response With Atezolizumab in Early Triple-Negative Breast Cancer
The addition of atezolizumab to carboplatin and nab-paclitaxel failed to improve complete response rates compared with chemotherapy alone in patients with triple-negative breast cancer...
Diagnostic and Treatment Technology Disparities Among Patients With Colorectal Cancer
Researchers have found racial disparities in how the presence of cancer-related diagnostic and treatment technology is related to colorectal cancer patient outcomes in Georgia...
Nathalie D. McKenzie: Practicing Wellness to Reduce Burnout
Richard M. Stone: ADMIRAL Trial in FLT3-Mutant Advanced AML
Jame Abraham: Time to Treatment Is a Priority
Maura Gillison: Immunotherapy for Head/Neck Squamous Cell Carcinoma
Sonali M. Smith: Checkpoint Blockade in Patients With Diffuse Large B-Cell Lymphoma
Enfortumab Vedotin in Metastatic Urothelial Carcinoma
In the phase I EV-101 trial reported in the Journal of Clinical Oncology, Rosenberg et al found that the antibody-drug conjugate enfortumab vedotin had no maximum tolerated dose and was active in patients with metastatic urothelial carcinoma at the dose selected for phase II evaluation. The agent...
Impact of Genes on Total Number and Type of Nevi
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
Cervical Cancer Recurrence: Open vs Minimally Invasive Radical Hysterectomy
A multi-institutional retrospective study reported in the Journal of Clinical Oncology by Shitanshu Uppal, MBBS, and colleagues showed that minimally invasive radical hysterectomy was associated with a higher risk of disease recurrence vs open abdominal hysterectomy in women undergoing surgery for...
Biomarker Analysis in the COMBI-AD Trial of Adjuvant Dabrafenib Plus Trametinib in BRAF V600–Mutant Stage III Melanoma
In an exploratory biomarker analysis from the COMBI-AD trial, reported in The Lancet Oncology, Dummer et al found that tumor mutational burden (TMB) and interferon-gamma gene-signature profiles might be associated with an augmented benefit of adjuvant dabrafenib plus trametinib in resected BRAF...
Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
Immune-Related Adverse Events in Patients With Cancer Receiving Influenza Vaccination During Treatment With Pembrolizumab
In a study reported in JCO Oncology Practice, Failing et al found that influenza vaccination did not increase the incidence of immune-related adverse events among patients receiving pembrolizumab for various cancers. On multivariate analysis, influenza vaccination was associated with a...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
Luis I. Ruffolo, MD, on Pancreatic Cancer: Augmenting Immunotherapy With Antibody Blockade of Semaphorin 4D
Franck Pagès, MD, PhD, on Stage III Colon Cancer: IDEA Study on a Risk Assessment Tool
Eyal Meiri, MD, on Pembrolizumab in Colorectal Cancer: Results From the TAPUR Study
Julie N. Graff, MD, on Castration-Resistant Prostate Cancer: Results From KEYNOTE-199 on Pembrolizumab Plus Enzalutamide
